简介：

简介：Thedevelopmentofcancernanotherapeuticshasattractedgreatinterestintherecentdecade.Cancernanotherapeuticshaveovercomeseverallimitationsofconventionaltherapies,suchasnonspecificbiodistribution,poorwatersolubility,andlimitedbioavailability.Nanoparticleswithtunedsizeandsurfacecharacteristicsarethekeycomponentsofnanotherapeutics,andaredesignedtopassivelyoractivelydeliveranti-cancerdrugstotumorcells.Weprovideanoverviewofnanoparticle-baseddrugdeliverymethodsandcancertherapiesbasedontumor-targetingdeliverystrategiesthathavebeendevelopedinrecentyears.

简介：Inthefightagainstcancer,controlleddrugdeliverysystemshaveemergedtoenhancethetherapeuticefficacyandsafetyofanti-cancerdrugs.Amongthesesystems,mesoporoussilicananoparticles(MSNs)withafunctionalsurfacepossessobviousadvantagesandwerethusrapidlydevelopedforcancertreatment.Manystimuli-responsivematerials,suchasnanoparticles,polymers,andinorganicmaterials,havebeenappliedascapsandgatekeeperstocontroldrugreleasefromMSNs.ThisreviewpresentsanoverviewoftherecentprogressintheproductionofpH-responsiveMSNsbasedonthepHgradientbetweennormaltissuesandthetumormicroenvironment.Fourmaincategoriesofgatekeeperscanrespondtoacidicconditions.Thesecategorieswillbedescribedindetail.

简介：Objective:TheUnionforInternationalCancerControl(UICC)Node(N)classificationisthemostcommonusedstagingmethodfortheprognosisofgastriccancer.Itdemandsadequate,atleast16lymphnodes(LNs)tobedissected;thereforedifferentstagingsystemswereinvented.Methods:BetweenMarch2005andMarch2010,164patientswereevaluatedattheDepartmentofGeneralSurgeryintheKenézyGyulaHospitalandattheDepartmentofGeneral,ThoracicandVascularSurgeryintheKaposiMórHospital.The6th,7thand8thUICCN-stagingsystems,thenumberofexaminedLNs,thenumberofharvestednegativeLNs,themetastaticlymphnoderatio(MLR)andthelogoddsofpositiveLNs(LODDS)weredeterminedtomeasuretheir5-yearsurvivalratesandtocomparethemtoeachother.Results:Theoverall5-yearsurvivalrateforallpatientswas55.5%withamedianoverallsurvivaltimeof102months.Thetumorstage,gender,UICCN-stages,MLRandtheLODDSweresignificantprognosticfactorsforthe5-yearsurvivalwithunivariateanalysis.The6thUICCN-stagedidnotfollowtheadequateriskincomparingN2vs.N0andN3vs.N0withmultivariateinvestigation.ComparisonofperformancesoftheresidualNclassificationsprovedthattheLODDSsystemwasfirstinthepredictionofprognosisduringtheevaluationofallpatientsandincaseswithlessthan16harvestedLNs.TheMLRgavethebestprognosticpredictionwhenadequate(morethanorequalto16)lymphadenectomywasperformed.Conclusions:WesuggesttheapplicationofLODDSsystemroutinelyinwesternpatientsandtheusageofMLRclassificationincaseswithextendedlymphadenectomy.

简介：Objective:Theaimsofthiscross-sectionaldescriptivestudyweretoevaluatethequalityoflife(QoL)ofthelungcancerpatientsandtoinvestigatedifferencesinQoLwithrespecttogeneralandmedicalcharacteristics.Methods:Structuredquestionnaires(EORTCQLQ-C30andQLQ-LC13)wereusedamong106consecutivelungcancerpatientsfordatacollectionduring1Jan2002to31Dec2002.Thet-testandone-wayanalysisofvariance(ANOVA)wereusedtocomparedifferencesofQoLbetweenthefactorsata5%levelofsignificance.Results:Thestudyrevealedthatthequalityoflifeofthelungcancerpatientswereworsethanreferencevalue.Theyoung,maleandmarriedpatientgroupshadbetterQoL.PatientswithlowereducationorincomehadworseQoL.SmallcelllungcancerpatientsreportedpoorerQoLthannon-smallcelllungcancerpatients.ThequalityoflifeinpatientsatlatestageorwithmetastasishadworseQoL.Thetreatmentscouldworsenthequalityoflife.Whentheoutcomesofthefourtreatmentswerecompared,thesurgerygroupdisplayedthebestqualityoflifeandthecombinedtreatmentgroupdisplayedtheworstqualityoflife.Conclusion:Theresultsofthepresentstudyshowedimportantramificationsforclinicians,researchersandpolicy-makers.